Drug firm FDC Ltd. launched two variants of Covid-19 drug Favipiravir in India at ₹55 per tablet

Drug company FDC has launched PiFLU and Favenza, two variants of Favipiravir effective in the treatment of corona virus in India.

Researchers from all over the world are busy making the Coronavirus vaccine. Different stages of vaccine trials are underway in many countries. Meanwhile, the drug company FDC has launched two variants of Favipiravir effective in treating Covid-19 in India, PiFLU, and Favenza. Its use has been approved for the treatment of patients with mild and moderate symptoms of corona.

FDC spokesman Mayank Tikkha said that thousands of new cases of corona infections are coming to the country every day. PiFLU and Fevenza will help prevent the worsening of patients. Together with the government and health sector people, we will make both these medicines available throughout the country. Favipiravir is an antiviral enzyme that specifically inhibits RNA polymerase and viral replication of influenza and SARCov-2 viruses.

FDC Limited has priced these two variants of Favipiravir at just Rs 55 per tablet. The Drug Controller General of India has approved the antiviral drug Favipiravir. It has been shown to be helpful in the recovery of corona patients with mild and moderate symptoms.

India has become the third most infected country in the world in Kovid-19. Due to this, the economy has suffered a setback. Recently, the pharma company Dr. Reddy’s Laboratories also launched the Coronavirus drug. This company has introduced the drug as Avigan. The company has launched this drug in a pack of 122 tablets. The expiry of medicine will be for two years. The company will also provide a drug-free home delivery service in 41 cities of the country.

Related Articles

Back to top button